Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
Novartis
Galapagos NV
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
BeOne Medicines
National Institutes of Health Clinical Center (CC)
AbbVie
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Genentech, Inc.
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Hoffmann-La Roche
Case Comprehensive Cancer Center
Taiho Oncology, Inc.
Thomas Jefferson University
Dartmouth-Hitchcock Medical Center
Celgene
Pfizer